Skip Ribbon Commands
Skip to main content
Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Independence position on preferred long-acting insulin​

December 21, 2021

Independence continues to designate Lantus® (insulin glargine) as one of its preferred long-acting insulin drugs used to manage diabetes.

On July 28, 2021, the U.S. Food and Drug Administration (FDA) approved new NDCs for ​​Semglee® and its authorized generic insulin glargine-yfgn as interchangeable biosimilars to Lantus. However, when considering all discounts that are passed along to members or their employer groups, Lantus is still the more cost-effective product. 

During the first quarter of 2022, Independence will continue to monitor the marketplace regarding these products and review its position on these medications as needed. Member disruption and continued access to cost-effective medications will be considered.

Providers will be notified via the Provider News Center if any changes are made to the preferred drug.

This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.